Article Sidebar
Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Studies on intestinal passage of flumequine and oxytetracycline-loaded MIL-100 (Fe) in the presence of divalent ions
Abstract
Purpose: To compare the intestinal absorption of flumequine (FLM) and oxytetracycline (OTC) in encapsulated and non-encapsulated forms in the presence of divalent ions.
Methods: MIL-100 (Fe) nanoparticles were synthesized under hydrothermal conditions from a mixture of iron carboxylate and trimesic acid (organic linker), and then used to encapsulate OTC and FLM. Permeation of the various formulations through the mouse jejunum was evaluated in Ussing chamber.
Results: There was significant (p ˂ 0.05) increase in the intestinal flux of encapsulated OTCs (OTCNPs, 0.072 ± 0.016 μg/h/cm2), compared to that of non-encapsulated OTCs (0.021 ± 0.05 μg/h/cm2). Moreover, the intestinal flux of encapsulated FLMs (FLM-NPs, 0.045 ± 0.006 μg/h/cm2) was significantly higher than that of non-encapsulated FLMs (0.004 ± 0.0008 μg/ h/cm2, p ˂ 0.05).
Conclusion: The intestinal flux of encapsulated antibiotics is significantly enhanced in the presence of MIL-100 (Fe), thereby preventing their chelation by divalent ions in solution, and thus improving their intestinal absorption.
Keywords: MIL-100 (Fe), Intestinal bioavailability, Mice, Oxytetracycline, Flumequine
